Vortex Biosciences Revenue and Competitors

Circulating Tumor Cells (CTCs) are cancer cells, which have detached from the primary tumor and have entered the patient bloodstream. These CTCs are known to be the key cause of secondary tumors in patients. As a result, the number and type of CTCs in a patient blood is highly indicative of the status of cancer in that patient. CTCs provide insight into the source of the primary tumor, grade, invasiveness, response to therapy and recurrence. As an indication, approximately 1.5 million new cancer patients are diagnosed per year in the United States, and around 20 million existing patients are undergoing monitoring. Vortex Biosciences has a mission to be the innovation leader in CTC capture technology delivering diagnostic tests that improve therapeutic decisions and save lives. We have introduced the VTX-1 Liquid Biopsy System which automates the isolation and collection of CTCs from blood samples. Our platform has the potential to revolutionize cancer diagnosis leading to better therapeutic outcomes. Further potential applications include clinical research and the identification of cancer therapies and drug targets. To learn more about this transformative technology, please visit our website at www.vortexbiosciences.com